Karyopharm Therapeutics
KPTI
KPTI
49 hedge funds and large institutions have $13.7M invested in Karyopharm Therapeutics in 2025 Q1 according to their latest regulatory filings, with 4 funds opening new positions, 8 increasing their positions, 30 reducing their positions, and 42 closing their positions.
New
Increased
Maintained
Reduced
Closed
more call options, than puts
Call options by funds: $ | Put options by funds: $
more ownership
Funds ownership: →
less funds holding
Funds holding: →
less capital invested
Capital invested by funds: $ → $
73% less repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 30
90% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 42
Holders
49
Holding in Top 10
–
Calls
$581K
Puts
$95K
Top Buyers
| 1 | +$1.3M | |
| 2 | +$1.19M | |
| 3 | +$1.04M | |
| 4 |
EP
Eversept Partners
New York
|
+$1.01M |
| 5 |
UBS Group
Zurich,
Switzerland
|
+$716K |
Top Sellers
| 1 | -$1.91M | |
| 2 | -$1.08M | |
| 3 | -$863K | |
| 4 |
KCM
Kennedy Capital Management
St Louis,
Missouri
|
-$808K |
| 5 |
UOC
UBS O'Connor
Chicago,
Illinois
|
-$643K |